

Anthem Biosciences Limited

(Formerly known as Anthem Biosciences Pvt. Ltd.)

49, F1 & F2, Canara Bank Road,
Bommasandra Industrial Area, Phase - I
Bommasandra, Bengaluru - 560 099
Karnataka, India

CIN : U24233KA2006PLC039703

Tel : +91 80 6672 4000

Fax : +91 80 6672 4020

www.anthembio.com

Date: November 08, 2025

To,
BSE Limited,
20th Floor, P.J. Towers,
Dalal Street,
Mumbai - 400001.
BSE Scrip Code: 544449

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Scrip Symbol: ANTHEM

Subject: Press Release on the Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2025

Dear Sir/Ma'am

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a copy of the Press Release on the Unaudited Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2025.

The same is also available on the Company's website at <https://www.anthembio.com/investor.html>.

We request you to kindly take the same on record.

Thanking you,

Yours truly,
For Anthem Biosciences Limited
(Formerly known as Anthem Biosciences Private Limited)

Digitally signed by
DIVYA PRASAD
Date: 2025.11.08
19:42:45 +05'30'

Divya Prasad
Company Secretary & Compliance Officer
Membership No: A41438

Press Release: Anthem Q2 & H1 FY26 Results

Consolidated Revenue from Operations for the quarter stood at ₹5,500 Mn.

EBITDA for the quarter was ₹2,661 Mn.

PAT at ₹1,734 Mn, with PAT margins at 29%.

For the first half, Consolidated Revenue from Operations was ₹10,902 Mn.

EBITDA for H1 FY26 was ₹4,804 Mn.

PAT at ₹3,092 Mn, with PAT margins at 27%.

Bengaluru, November 08, 2025: Anthem Biosciences Limited (BSE: 544449 | NSE: ANTHEM | INE0CZ201020), an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”), today announced unaudited results for the second quarter and half year ended September 30, 2025 as approved by its Board of Directors.

Q2 & H1 FY26 Financial Highlights:

| Particulars (₹ Mn) | Q2FY26 | Q2FY25 | YoY | Q1FY26 | QoQ | H1 FY26 | H1 FY25 | YoY |
|------------------------------|--------|--------|---------|--------|---------|---------|---------|-------|
| Revenue from Operations | 5,500 | 5,250 | 4.8% | 5,402 | 1.8% | 10,902 | 8,636 | 26.3% |
| <i>CRDMO</i> | 4,719 | 4,351 | 8.5% | 4,527 | 4.2% | 9,267 | 7,006 | 32.3% |
| <i>Specialty Ingredients</i> | 781 | 899 | (13.1%) | 875 | (10.7%) | 1,636 | 1,630 | 0.4% |
| Other Income | 482 | 278 | 73.2% | 228 | 111.4% | 710 | 473 | 50.2% |
| Total Revenues | 5,983 | 5,528 | 8.2% | 5,630 | 6.3% | 11,613 | 9,109 | 27.5% |
| EBITDA | 2,661 | 2,231 | 19.3% | 2,143 | 24.2% | 4,804 | 3,634 | 32.2% |
| Profit before tax | 2,296 | 1,995 | 15.1% | 1,862 | 23.3% | 4,159 | 3,175 | 31.0% |
| Profit after tax | 1,734 | 1,619 | 7.1% | 1,358 | 27.7% | 3,092 | 2,443 | 26.6% |

H1 FY26 Key Financial Highlights:

- Consolidated Revenue from Operations was ₹10,902 Mn for the quarter
 - *CRDMO business delivered ₹9,267 Mn revenues*
 - *Specialty Ingredients delivered ₹1,636 Mn revenues*
- EBITDA was ₹4,804 Mn, with EBITDA margins at 41.4%
 - *EBITDA for H1 FY26 includes Other Income of ₹710 Mn (H1 FY25: ₹473 Mn)*
 - *Other Operating Income on account of forex gain (net) and RoDTEP incentives is ₹340 Mn (Q2 FY25: ₹114 Mn)*
 - *Financial and other Non-Operating Income is ₹370 Mn (Q2 FY25: ₹359 Mn)*
- PAT (Profit After Tax) was ₹3,092 Mn, with PAT margins at 26.6%
- Net Cash position as of Sept 30, 2025, is ₹9,934 Mn

Q2 FY26 Key Financial Highlights:

- Consolidated Revenue from Operations was ₹5,500 Mn for the quarter
 - *CRDMO business delivered ₹4,719 Mn revenues*
 - *Specialty Ingredients delivered ₹781 Mn revenues*
- EBITDA was ₹2,661 Mn, with EBITDA margins at 44.5%
 - *EBITDA for Q2 FY26 includes Other Income of ₹482 Mn (Q2 FY25: ₹278 Mn)*
 - *Other Operating Income on account of forex gain (net) and RoDTEP incentives is ₹303 Mn (Q2 FY25: ₹38 Mn)*
 - *Financial and other Non-Operating Income is ₹179 Mn (Q2 FY25: ₹240 Mn)*
- PAT (Profit After Tax) was ₹1,734 Mn, with PAT margins at 29.0%

Commenting on the results, **Ajay Bhardwaj, Chairman, Managing Director and CEO, Anthem Biosciences Limited, said:** *“We are pleased to report a robust performance for Q2FY26, driven by our CRDMO revenue stream, which has delivered consistent performance over the past five quarters. Our commitment to continuous improvement, innovation, and responsible business practices remains unwavering. With this strong first-half performance, we are confident in our ability to sustain growth and create long-term value for all stakeholders”.*

Earnings Call:

Anthem Biosciences Limited will conduct earnings call at 12 noon (IST) on 10th November, 2025 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

Date and Time **10th November 2025, 12 Noon (IST) / 2:30 pm (SGT/HKT)**

Universal Dial-in +91 22 6280 1102 / +91 22 7115 8003

International Dial-in Singapore: 8001012045 | HK: 800964448 | USA: 186674 62133 | UK: 08081011573

Diamond Pass link [Diamond Pass Registration](#)

About Anthem: Incorporated in Bangalore on June 13, 2006, Anthem is an innovation-driven and technology-focused CRDMO with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem is one of the few companies in India with integrated New Chemical Entity (“NCE”) and New Biological Entity (“NBE”) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, Anthem serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. With the three pillars of innovation and technology, high quality standards, and a customer-first approach, Anthem is committed to solving problems in biology and chemistry using technology.

For more information, please visit
<https://anthembio.com/investor.html>

For further details, please feel free to contact:
investors.abl@anthembio.com | anthem@adfactorspr.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Anthem, nor our directors, assume any obligation to update any forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.